Bruun Jens M, Lihn Aina S, Pedersen Steen B, Richelsen Bjørn
Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus Sygehus, Tage Hansensgade 2, DK-8000 Aarhus C, Denmark.
J Clin Endocrinol Metab. 2005 Apr;90(4):2282-9. doi: 10.1210/jc.2004-1696. Epub 2005 Jan 25.
Human adipose tissue (AT) produces several adipokines including monocyte chemoattractant protein (MCP)-1, involved in the pathogenesis of atherosclerosis.
Human AT cultures, isolated adipocytes, and stromal-vascular cells were used to investigate the relationship among AT-resident macrophages, MCP-1, and adiposity and the regulation of MCP-1.
mRNA levels of specific macrophage markers (CD68 and CD14) are correlated with adiposity in sc AT and visceral AT (P < 0.05). MCP-1 production is higher in stromal-vascular cells vs. adipocytes (P < 0.01) and correlates with macrophage markers in both AT compartments (P < 0.05). MCP-1 release is higher in obese subjects (P < 0.05) and in VAT (P < 0.01), but after adjusting for AT-resident macrophages, the differences disappear. MCP-1 is stimulated by IL-1beta, TNF-alpha, IL-8, IL-4, and IL-6 + IL-6-soluble receptor and is decreased by dexamethasone, IL-10, metformin, and thiazolidinediones.
MCP-1 is correlated with specific macrophage markers, adiposity, and AT localization, but the relationship seems to be related to the number of AT-resident macrophages. Despite this, MCP-1 may be involved in obesity-related health complications, and the decrease of MCP-1 by metformin and thiazolidinediones suggests that these antidiabetic compounds have antiinflammatory properties improving the low-grade inflammatory state observed in obesity.
人体脂肪组织(AT)可产生多种脂肪因子,包括单核细胞趋化蛋白(MCP)-1,其参与动脉粥样硬化的发病机制。
利用人体AT培养物、分离的脂肪细胞和基质血管细胞,研究AT驻留巨噬细胞、MCP-1与肥胖之间的关系以及MCP-1的调节机制。
皮下AT和内脏AT中特定巨噬细胞标志物(CD68和CD14)的mRNA水平与肥胖相关(P<0.05)。基质血管细胞中MCP-1的产生高于脂肪细胞(P<0.01),且在两个AT区室中均与巨噬细胞标志物相关(P<0.05)。肥胖受试者(P<0.05)和内脏脂肪组织(VAT)中MCP-1的释放较高(P<0.01),但在调整AT驻留巨噬细胞后,差异消失。MCP-1受到白细胞介素-1β、肿瘤坏死因子-α、白细胞介素-8、白细胞介素-4以及白细胞介素-6+白细胞介素-6可溶性受体的刺激,而地塞米松、白细胞介素-10、二甲双胍和噻唑烷二酮可使其降低。
MCP-1与特定巨噬细胞标志物、肥胖及AT定位相关,但这种关系似乎与AT驻留巨噬细胞的数量有关。尽管如此,MCP-1可能参与肥胖相关的健康并发症,二甲双胍和噻唑烷二酮使MCP-1降低,提示这些抗糖尿病化合物具有抗炎特性,可改善肥胖中观察到的低度炎症状态。